New functions of the major histocompatibility complex class II-specific transcription factor RFXANK revealed by a high-resolution mutagenesis study

Molecular and Cellular Biology

Volumn 25, Issue 19, 2005, Pages 8607-8618

  Krawczyk, Michal ^a   Masternak, Krzysztof ^a,b   Zufferey, Madeleine ^a   Barras, Emmanuèle ^a   Reith, Walter ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b NOVIMMUNE SA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANKYRIN; ENHANCEOSOME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ANKRA2; TRANSCRIPTION FACTOR RFX5; TRANSCRIPTION FACTOR RFXANK; TRANSCRIPTION FACTOR RFXAP; UNCLASSIFIED DRUG;

ARTICLE; CHROMATIN; COMPLEX FORMATION; CONTROLLED STUDY; GENE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MUTAGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; CELL LINE; CELL SEPARATION; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; FLOW CYTOMETRY; GLUTATHIONE TRANSFERASE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOPRECIPITATION; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS; MUTATION; NUCLEAR PROTEINS; PLASMIDS; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; PROTEIN BIOSYNTHESIS; PROTEIN CONFORMATION; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; SEQUENCE HOMOLOGY, AMINO ACID; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 25444478560     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.25.19.8607-8618.2005     Document Type: Article

References (50)

1. Benoist, C., and D. Mathis. 1990. Regulation of major histocompatibility complex class II genes: X, Y and other letters of the alphabet. Annu. Rev. Immunol. 8:681-715.
2. Beresford, G. W., and J. M. Boss. 2001. CIITA coordinates multiple histone acetylation modifications at the HLA-DRA promoter. Nat. Immunol. 2:652-657.
3. Bontron, S., C. Ucla, B. Mach, and V. Steimle. 1997. Efficient repression of endogenous major histocompatibility complex class II expression through dominant negative CIITA mutants isolated by a functional selection strategy. Mol. Cell. Biol. 17:4249-4258.
4. Boss, J. M., and P. E. Jensen. 2003. Transcriptional regulation of the MHC class II antigen presentation pathway. Curr. Opin. Immunol. 15:105-111.
5. Charron, D. J., and H. O. McDevitt. 1979. Analysis of HLA-D region-associated molecules with monoclonal antibody. Proc. Natl. Acad. Sci. USA 76:6567-6571.
6. Cresswell, P. 1994. Assembly, transport, and function of MHC class II molecules. Annu. Rev. Immunol. 12:259-293.
7. DeSandro, A. M., U. M. Nagarajan, and J. M. Boss. 2000. Associations and interactions between bare lymphocyte syndrome factors. Mol. Cell. Biol. 20:6587-6599.
8. Durand, B., P. Sperisen, P. Emery, E. Barras, M. Zufferey, B. Mach, and W. Reith. 1997. RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency. EMBO J. 16:1045-1055.
9. Foord, R., I. A. Taylor, S. G. Sedgwick, and S. J. Smerdon. 1999. X-ray structural analysis of the yeast cell cycle regulator Swi6 reveals variations of the ankyrin fold and has implications for Swi6 function. Nat. Struct. Biol. 6:157-165.
10. Fuerst, T. R., E. G. Niles, F. W. Studier, and B. Moss. 1986. Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc. Natl. Acad. Sci. USA 83:8122-8126.
11. Griscelli, C., B. Lisowska-Grospierre, and B. Mach. 1993. Combined immunodeficiency with defective expression in MHC class II genes, p. 141-154. In F. S. Rosen and M. Seligman (ed.), Immunodeficiencies. Harwood Academic Publishers, Chur, Switzerland.
12. Guex, N., and M. C. Peitsch. 1997. SWISS-MODEL and the Swiss-Pdb-Viewer: an environment for comparative protein modeling. Electrophoresis 18:2714-2723.
13. Hake, S. B., K. Masternak, C. Kammerbauer, C. Janzen, W. Reith, and V. Steimle. 2000. CIITA leucine-rich repeats control nuclear localization, in vivo recruitment to the major histocompatibility complex (MHC) class II enhanceosome, and MHC class II gene transactivation. Mol. Cell. Biol. 20:7716-7725.
14. Harten, J. A., and J. P. Ting. 2000. Class II transactivator: mastering the art of major histocompatibility complex expression. Mol. Cell. Biol. 20:6185-6194.
15. Hume, C. R., L. A. Shookster, N. Collins, R. O'Reilly, and J. S. Lee. 1989. Bare lymphocyte syndrome: altered HLA class II expression in B cell lines derived from two patients. Hum. Immunol. 25:1-11.
16. Jabrane-Ferrat, N., N. Nekrep, G. Tosi, L. Esserman, and B. M. Peterlin. 2003. MHC class II enhanceosome: how is the class II transactivator recruited to DNA-bound activators? Int. Immunol. 15:467-475.
17. Landmann, S., J. M. Waldburger, K. Masternak, A. Muhlethaler-Mottet, and W. Reith. 2003. CIITA and the MHCII enhanceosome in the regulation of MHCII expression. Curr. Genom. 4:343-363.
18. LeibundGut-Landmann, S., J. M. Waldburger, M. Krawczyk, L. A. Otten, T. Suter, A. Fontana, H. Acha-Orbea, and W. Reith. 2004. Specificity and expression of CIITA, the master regulator of MHC class II genes. Eur. J. Immunol. 34:1513-1525.
19. Lin, J. H., A. Makris, C. McMahon, S. E. Bear, C. Patriotis, V. R. Prasad, R. Brent, E. A. Golemis, and P. N. Tsichlis. 1999. The ankyrin repeat-containing adaptor protein Tvl-1 is a novel substrate and regulator of Raf-1. J. Biol. Chem. 274:14706-14715.
20. Long, A. B., and J. M. Boss. 2005. Evolutionary conservation and characterization of the bare lymphocyte syndrome transcription factor RFX-B and its paralogue ANKRA2. Immunogenetics 56:788-797.
21. Mantovani, R. 1999. The molecular biology of the CCAAT-binding factor NF-Y. Gene 239:15-27.
22. Masternak, K., E. Barras, M. Zufferey, B. Conrad, G. Corthals, R. Aebersold, J. C. Sanchez, D. F. Hochstrasser, B. Mach, and W. Reith. 1998. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. Nat. Genet. 20:273-277.
23. Masternak, K., A. Muhlethaler-Mottet, J. Villard, M. Zufferey, V. Steimle, and W. Reith. 2000. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. Genes Dev. 14:1156-1166.
24. Masternak, K., N. Peyraud, M. Krawczyk, E. Barras, and W. Reith. 2003. Chromatin remodeling and extragenic transcription at the MHC class II locus control region. Nat. Immunol. 4:132-137.
25. Masternak, K., and W. Reith. 2002. Promoter-specific functions of CIITA and the MHC class II enhancesosome in transcriptional activation. EMBO J. 21:1379-1388.
26. Matheux, F., A. Ikinciogullari, D. A. Zapata, E. Barras, M. Zufferey, F. Dogu, J. R. Regueiro, W. Reith, and J. Villard. 2002. Direct genetic correction as a new method for diagnosis and molecular characterization of MHC class II deficiency. Mol. Ther. 6:824-829.
27. Moreno, C. S., G. W. Beresford, P. Louis-Plence, A. C. Morris, and J. M. Boss. 1999. CREB regulates MHC class II expression in a CIITA-dependent manner. Immunity 10:143-151.
28. Mosavi, L. K., T. J. Cammett, D. C. Desrosiers, and Z. Y. Peng. 2004. The ankyrin repeat as molecular architecture for protein recognition. Protein Sci. 13:1435-1448.
29. Muhlethaler-Mottet, A., M. Krawczyk, K. Masternak, C. Spilianakis, A. Kretsovali, J. Papamatheakis, and W. Reith. 2004. The S box of MHC class II promoters is a key determinant for recruitment of the transcriptional coactivator CIITA. J. Biol. Chem. 279:40529-40535.
30. Nagarajan, U. M., A. B. Long, M. T. Harreman, A. H. Corbett, and J. M. Boss. 2004. A hierarchy of nuclear localization signals governs the import of the regulatory factor X complex subunits and MHC class II expression. J. Immunol. 173:410-419.
31. Nagarajan, U. M., P. Louis-Plence, A. DeSandro, R. Nilsen, A. Bushey, and J. M. Boss. 1999. RFX-B is the gene responsible for the most common cause of the bare lymphocyte syndrome, an MHC class II immunodeficiency. Immunity 10:153-162.
32. Nagarajan, U. M., A. Peijnenburg, S. J. Gobin, J. M. Boss, and P. J. van den Elsen. 2000. Novel mutations within the RFX-B gene and partial rescue of MHC and related genes through exogenous class II transactivator in RFX-B-deficient cells. J. Immunol. 164:3666-3674.
33. Nekrep, N., M. Geyer, N. Jabrane-Ferrat, and B. M. Peterlin. 2001. Analysis of ankyrin repeats reveals how a single point mutation in RFXANK results in bare lymphocyte syndrome. Mol. Cell. Biol. 21:5566-5576.
34. Nekrep, N., N. Jabrane-Ferrat, and B. M. Peterlin. 2000. Mutations in the bare lymphocyte syndrome define critical steps in the assembly of the regulatory factor X complex. Mol. Cell. Biol. 20:4455-4461.
35. Peretti, M., J. Villard, E. Barras, M. Zufferey, and W. Reith. 2001. Expression of the three human major histocompatibility complex class II isotypes exhibits a differential dependence on the transcription factor RFXAP. Mol. Cell. Biol. 21:5699-5709.
36. Rader, K., R. A. Orlando, X. Lou, and M. G. Farquhar. 2000. Characterization of ANKRA, a novel ankyrin repeat protein that interacts with the cytoplasmic domain of megalin. J. Am. Soc. Nephrol. 11:2167-2178.
37. Reith, W., and B. Mach. 2001. The bare lymphocyte syndrome and the regulation of mhc expression. Annu. Rev. Immunol. 19:331-373.
38. Reith, W., S. Satola, C. Herrero Sanchez, I. Amaldi, B. Lisowska-Grospierre, C. Griscelli, M. R. Hadam, and B. Mach. 1988. Congenital immunodeficiency with a regulatory defect in MHC class II gene expression lacks a specific HLA-DR promoter binding protein, RF-X. Cell 53:897-906.
39. Schwede, T., J. Kopp, N. Guex, and M. C. Peitsch. 2003. SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res. 31:3381-3385.
40. Sedgwick, S. G., I. A. Taylor, A. C. Adam, A. Spanos, S. Howell, B. A. Morgan, M. K. Treiber, N. Kanuga, G. R. Banks, R. Foord, and S. J. Smerdon. 1998. Structural and functional architecture of the yeast cell-cycle transcription factor swi6. J. Mol. Biol. 281:763-775.
41. Spilianakis, C., A. Kretsovali, T. Agalioti, T. Makatounakis, D. Thanos, and J. Papamatheakis. 2003. CIITA regulates transcription onset viaSer5-phosphorylation of RNA Pol II. EMBO J. 22:5125-5136.
42. Steimle, V., B. Durand, E. Barras, M. Zufferey, M. R. Hadam, B. Mach, and W. Reith. 1995. A novel DNA binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). Genes Dev. 9:1021-1032.
43. Steimle, V., L. A. Otten, M. Zufferey, and B. Mach. 1993. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency. Cell 75:135-146.
44. Ting, J. P., and J. Trowsdale. 2002. Genetic control of MHC class II expression. Cell 109(Suppl.):S21-S33.
45. Tsang, S. Y., M. Nakanishi, and B. M. Peterlin. 1990. Mutational analysis of the DRA promoter: as-acting sequences and irans-acting factors. Mol. Cell. Biol. 10:711-719.
46. Viret, C., and C. A. J. Janeway. 1999. MHC and T cell development. Rev. Immunogenet. 1:91-104.
47. Wiszniewski, W., M. C. Fondaneche, N. Lambert, K. Masternak, C. Picard, L. Notarangelo, K. Schwartz, J. Bal, W. Reith, C. Alcaide, B. de Saint, A. Fischer, and B. Lisowska-Grospierre. 2000. Founder effect for a 26-bp deletion in the RFXANK gene in North African major histocompatibility complex class II-deficient patients belonging to complementation group B. Immunogenetics 51:261-267.
48. Wiszniewski, W., M. C. Fondaneche, P. Louise-Plence, A. Prochnicka-Chalufour, F. Selz, C. Picard, F. Le Deist, J. F. Eliaou, A. Fischer, and B. Lisowska-Grospierre. 2003. Novel mutations in the RFXANK gene: RFX complex containing in-vitro-generated RFXANK mutant binds the promoter without transactivating MHC II. Immunogenetics 54:747-755.
49. Zhu, X. S., M. W. Linhoff, G. Li, K. C. Chin, S. N. Maity, and J. P. Ting. 2000. Transcriptional scaffold: CIITA interacts with NF-Y, RFX, and CREB to cause stereospecific regulation of the class II major histocompatibility complex promoter. Mol. Cell. Biol. 20:6051-6061.
50. Zika, E., and J. P. Ting. 2005. Epigenetic control of MHC-II: interplay between CIITA and histone-modifying enzymes. Curr. Opin. Immunol. 17:58-64.